The Quality of Life and Hormonal Disturbances in Testicular Cancer Survivors in Cisplatin Era-Reference-Cited by-同舟云学术

The Quality of Life and Hormonal Disturbances in Testicular Cancer Survivors in Cisplatin Era

Published:2007-11 Issue:5 Volume:52 Page:1448-1455
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Wiechno Paweł,Demkow Tomasz,Kubiak Krzysztof,Sadowska Małgorzata,Kamińska Janina

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG);Schmoll;Ann Oncol,2004

2. Guidelines on testicular cancer;Albers;Eur Urol,2005

3. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure;Geldart;BJU Int,2006

4. Wrześniewski K, Sosnowski T, Matusik D. [State trait anxiety inventory (STAI), Polish validation]. Warsaw: Pracownia Testów Psychologicznych Polskiego Towarzystwa Psychologicznego: Warsaw; 2002.

5. Evaluation of long-term toxicity after chemotherapy for testicular cancer;Bokemeyer;J Clin Oncol,1996

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency;Clinical Genitourinary Cancer;2023-08

2. Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot Study;Annals of Behavioral Medicine;2023-04-20

3. Changes in male sexuality after urologic cancer: a narrative review;International braz j urol;2023-04

4. Sexual function and fertility preservation in testicular cancer survivors;Journal of Men's Health;2023

5. A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention);Clinical Genitourinary Cancer;2022-10